KDR and non-small cell lung carcinoma: Although paracrine and autocrine activation of the EGFR and the VEGFR pathways have a key role in the development and progression of the majority of epithelial cancers including NSCLC, only a subgroup of NSCLC patients benefits of treatments with drugs targeting the EGFR or the VEGFR pathways (Morgillo et al, 2007).